Standard Biotools (LAB) Total Non-Current Liabilities (2010 - 2026)

Standard Biotools (LAB) has 17 years of Total Non-Current Liabilities data on file, last reported at $73.5 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 39.47% year-over-year to $73.5 million in Q1 2026; TTM through Mar 2026 was $73.5 million, a 39.47% decrease from a year earlier, with the FY2025 full-year figure at $142.2 million, up 1.93% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $73.5 million, down from $142.2 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for LAB reached as high as $248.3 million in Q1 2022 and fell as low as $73.5 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $159.0 million across 5 years, with a median of $158.7 million in 2023.
• Across the five-year window, Total Non-Current Liabilities jumped 37.29% in 2022 and sank 39.47% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $159.6 million in 2022, then slipped by 0.48% to $158.8 million in 2023, then retreated by 12.12% to $139.6 million in 2024, then advanced by 1.93% to $142.2 million in 2025, then slumped by 48.3% to $73.5 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $73.5 million in Q1 2026, $142.2 million in Q4 2025, and $138.8 million in Q3 2025.